Recommendation of the President – Imfinzi (durvalumab)
On 23 December 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 208/2025 on the reimbursement of the medicinal product Imfinzi (durvalumab) under the B.6 drug program “Treatment of patients with lung cancer (ICD-10: C34) and pleural mesothelioma (ICD-10: C45)”